# EXCALIBER-RRMM: HCP commentary report

> 664 verified statements (248 from speakers with a confirmed clinical role) from 52 commentary sources · 12 findings · updated Oct 18, 2026

## Report

- Trial: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT ID: NCT04975997
- Registry: https://clinicaltrials.gov/study/NCT04975997
- Sponsor: Celgene
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs: dexamethasone, daratumumab, bortezomib
- Indications: Multiple myeloma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-18
- Last checked: 2026-10-18
- Release hash: 72f581d56a26867e363420c64eba3fe5c0b59fb5cd562ab32ae490816155c2bb

## Counts

- HCP commentary sources screened: 61
- Sources cited by verified statements: 52
- Verified statements: 664
- From speakers with a confirmed clinical role: 248
- Findings: 12
- People found in screened sources: 40
- People identity-verified: 22
- Voices cited: 39

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

EXCALIBER-RRMM raises the question of where iberdomide with daratumumab and dexamethasone fits for patients with relapsed or refractory multiple myeloma. Clinicians discuss prior-treatment history and modern maintenance failure, comparisons with other relapse options, response durability, safety and supportive care, and patient preferences, access and referral. Other topics include dose selection and comparator design, minimal residual disease (MRD) measurement and routine testing, and evidence needed for accelerated approval and individual treatment decisions. The sources reviewed for this edition span different stages of evidence availability.

## Open Medical Affairs question

Which prior-treatment histories distinguish an evidence-supported IberDd discussion from extrapolation after modern maintenance failure?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Modern maintenance failure exposes unresolved treatment-fit questions
- F2. Favorable tolerability assessments coexist with consequential hematologic, infectious and vascular concerns
- F3. Manageability depends on individualized supportive care, dose holds and medication review
- F4. BCMA-first preferences coexist with conditional replacement of conventional triplets
- F5. Response-depth enthusiasm and reported PFS do not settle comparative treatment position
- F6. MRD-based early access divides assessments of evidentiary readiness
- F7. MRD’s meaning depends on denominator, timing and the intended clinical action
- F8. Dose optimization earns praise while comparator asymmetry draws scrutiny
- F9. CELMoD differentiation is argued biologically and clinically, but class taxonomy is contested
- F10. Patient choice and community feasibility depend on local capability and alternative-specific burdens
- F11. CELMoDs are envisioned as partners and sequencing tools, with investigational limits
- F12. Underrepresentation prompts applicability and recruitment concerns

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 39 | 29 | 15 | 14 | recorded | 3 |
| F2 | 52 | 43 | 17 | 11 | recorded | 3 |
| F3 | 32 | 24 | 12 | 11 | recorded | 3 |
| F4 | 40 | 28 | 13 | 10 | recorded | 2 |
| F5 | 46 | 37 | 30 | 20 | recorded | 4 |
| F6 | 75 | 64 | 27 | 22 | recorded | 3 |
| F7 | 47 | 35 | 8 | 9 | recorded | 3 |
| F8 | 41 | 24 | 13 | 11 | recorded | 3 |
| F9 | 39 | 31 | 13 | 8 | recorded | 3 |
| F10 | 112 | 74 | 14 | 15 | recorded | 4 |
| F11 | 69 | 47 | 12 | 10 | recorded | 3 |
| F12 | 9 | 4 | 3 | 2 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 9 | 11 | 0 | 2 | 17 | 42 | 6 | 7 posts and articles, 8 podcasts and video | yes |
| F2 | 11 | 7 | 3 | 19 | 12 | 63 | 17 | 8 posts and articles, 9 podcasts and video | yes |
| F3 | 11 | 5 | 5 | 3 | 8 | 33 | 6 | 7 posts and articles, 5 podcasts and video | yes |
| F4 | 12 | 7 | 1 | 14 | 6 | 40 | 3 | 7 posts and articles, 6 podcasts and video | yes |
| F5 | 7 | 12 | 1 | 13 | 13 | 48 | 7 | 18 posts and articles, 12 podcasts and video | yes |
| F6 | 20 | 23 | 3 | 1 | 28 | 84 | 10 | 14 posts and articles, 13 podcasts and video | yes |
| F7 | 21 | 7 | 1 | 8 | 10 | 68 | 1 | 4 posts and articles, 4 podcasts and video | yes |
| F8 | 6 | 3 | 4 | 8 | 20 | 50 | 8 | 4 posts and articles, 9 podcasts and video | yes |
| F9 | 12 | 7 | 0 | 10 | 10 | 46 | 15 | 3 posts and articles, 10 podcasts and video | yes |
| F10 | 47 | 25 | 12 | 12 | 16 | 121 | 25 | 4 posts and articles, 10 podcasts and video | yes |
| F11 | 32 | 16 | 0 | 6 | 15 | 71 | 14 | 1 post or article, 11 podcasts and video | yes |
| F12 | 4 | 0 | 0 | 1 | 4 | 9 | 4 | 3 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: Progression-free Survival (PFS): F4 (1 shared claims), F5 (9 shared claims), F6 (14 shared claims)
- Primary endpoint: Minimal Residual Disease (MRD) negative Complete Response (CR) at any time: F1 (1 shared claims), F5 (16 shared claims), F6 (2 shared claims), F7 (11 shared claims), F8 (1 shared claims)
- Secondary endpoints: F3 (2 shared claims), F5 (4 shared claims), F6 (6 shared claims), F7 (1 shared claims), F10 (2 shared claims)
- Population and setting: F1 (36 shared claims), F3 (1 shared claims), F4 (1 shared claims), F6 (1 shared claims), F7 (1 shared claims)
- The comparison: F4 (8 shared claims), F6 (1 shared claims), F8 (22 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (43 shared claims), F3 (5 shared claims), F5 (1 shared claims), F10 (2 shared claims)
- Design and conduct: F6 (1 shared claims), F8 (24 shared claims), F12 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F6. MRD-based early access divides assessments of evidentiary readiness

In a YouTube discussion, a speaker asked how the FDA might weigh co-primary endpoints when MRD-negativity data were mature but PFS remained immature, including scenarios with few PFS events or a possible early unfavorable PFS signal.

Source: YouTube video, 2026-03-31.

### F1. Modern maintenance failure exposes unresolved treatment-fit questions

In a YouTube discussion, a speaker asked whether trial participants were refractory to IMiDs and had previously received anti-CD38 therapy.

Source: YouTube video, 2026-04-10.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 13 sections | Paid |
| Verified statements with short source quotes and links | 664 | Paid |
| Trial aspects mapped | 15 | Free |
| Sources with links | 52 | Counts free |
| Speaker attribution for cited voices | 39 | Paid |

## Trial aspects

15 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-free Survival (PFS) | discussed | 24 | 19 |
| Primary endpoint: Minimal Residual Disease (MRD) negative Complete Response (CR) at any time | discussed | 29 | 20 |
| Secondary endpoints | discussed | 15 | 9 |
| Population and setting | discussed | 37 | 15 |
| The comparison | discussed | 30 | 13 |
| Safety and tolerability | discussed | 48 | 16 |
| Design and conduct | discussed | 25 | 11 |
| Position among early-relapse treatment alternatives | discussed | 38 | 13 |
| Shared decisions, community delivery and referral | discussed | 62 | 12 |
| CELMoD identity, mechanism and prior IMiD refractoriness | discussed | 39 | 13 |
| MRD-based approval, evidence release and early access | discussed | 71 | 27 |
| MRD ascertainment, routine monitoring and treatment decisions | discussed | 47 | 8 |
| Combinations, bridging and sequencing with immune therapies | discussed | 69 | 12 |
| Representation, applicability and recruitment equity | discussed | 9 | 3 |
| Supportive care, prescribing constraints and alternative-treatment management | discussed | 55 | 12 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 43 | 34 |
| Podcasts | 9 | 9 |
| YouTube | 7 | 7 |
| X videos | 2 | 2 |

- Screened window: 2024-07-04 to 2026-10-13
- Cited window: 2024-07-04 to 2026-10-13
- Retrieved: 2026-10-18

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
- Registry: NCT04975997 (https://clinicaltrials.gov/study/NCT04975997)
- Study IDs: CC-220-MM-002 · U1111-1260-2872 (UTN Number) · 2020-000431-49
- Sponsor: Celgene
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 939 (actual)
- Start: 2022-06-23 (actual)
- Primary completion: 2027-11-16 (estimated)
- Primary endpoint: Progression-free Survival (PFS) (Up to approximately 5 years)
- Primary endpoint: Minimal Residual Disease (MRD) negative Complete Response (CR) at any time (Up to approximately 5 years)
- Intervention: Dexamethasone (drug)
- Intervention: Daratumumab (drug)
- Intervention: Bortezomib (drug)
- Intervention: Iberdomide (drug)
- Intervention: Iberdomide (drug)
- Intervention: Iberdomide (drug)
- Intervention: Dexamethasone (drug)
- Intervention: Daratumumab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- Out of scope: 4 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
- 26 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition are a selected set of public and educational discussions, not a representative survey. Repeated recordings, related posts and account commentary cannot be counted as independent clinicians or used to estimate consensus.
- The discussions span anticipation of results, MRD-based approval accounts, subsequent PFS reporting and publication-sharing. Their information states differ; dates and sequence alone do not establish that an individual changed position.
- No full trial-results publication or trial protocol text is available for this report. A post sharing the manuscript does not supply its contents. Some speakers relied on press releases or prescribing information, so their numerical summaries and interpretations cannot be independently adjudicated here.
- The regulatory material is incomplete, including the absence of an exact daratumumab label. Regulatory descriptions, approval timing and label-based implementation details remain attributed statements rather than independently confirmed regulatory conclusions.
- Some potentially relevant recordings could not be read, and some passages could not be fully assessed. Discussion that used unnamed references or different spellings may also be missing.
- Several recording voices could not be identified. Their views remain unnamed, and account posts or relayed recommendations are not treated as direct statements by an inferred individual.
- The sources do not establish Mehak Trehan’s or Preetam Jain’s clinical role. Their posts are treated as attributed commentary, without assigning a specialty or practice setting.
- Some source accounts differ about prior treatment, eligibility, regimen components, comparator wording, MRD assessment and adverse-event rates. Those differences are preserved rather than reconciled into a single factual description.
- Cross-trial rankings are clinicians’ comparative interpretations, not head-to-head findings. Statements about other regimens retain their own population, setting, timing and supportive-care conditions.
- Future combinations, bridging strategies, immune-enhancement hypotheses and maintenance proposals are not treated as established benefits or prescribing recommendations for the EXCALIBER-RRMM regimen.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-18: current edition

Last checked for new commentary 2026-10-18. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Deep (664 verified statements)
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $3,400
- 6 months of weekly updates: $4,900
- 12 months of weekly updates: $6,800
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (22 now), at most $1,950; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/excaliber-rrmm-nct04975997
- Agents: POST https://www.erudio.com/api/orders with {"report": "excaliber-rrmm-nct04975997", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=excaliber-rrmm-04975997

## Cite

Erudio Health. EXCALIBER-RRMM (NCT04975997): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 18, 2026. https://www.erudio.com/reports/excaliber-rrmm-nct04975997

## Machine access

- JSON: https://www.erudio.com/reports/excaliber-rrmm-nct04975997.json
- Markdown: https://www.erudio.com/reports/excaliber-rrmm-nct04975997.md
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "excaliber-rrmm-04975997"}`